monoclonal antibodies – rituximab & obinutuzumab | rebecca beck, lymphoma australia
Published 4 years ago • 964 plays • Length 40:12Download video MP4
Download video MP3
Similar videos
-
3:48
monoclonal antibodies - living with lymphoma - chapter 10
-
1:35
emerging monoclonal antibodies for lymphoma therapy
-
14:02
debate: is obinutuzumab superior to rituximab in lymphoma? - no
-
12:52
debate: is obinutuzumab superior to rituximab in lymphoma? - yes
-
0:26
your life matters - rebecca's story
-
3:20
how monoclonal antibodies treat cancer
-
4:42
obinutuzumab extends pfs for follicular lymphoma in gallium trial
-
0:46
obinutuzumab | monoclonal antibody | dr pharma
-
4:34
obinutuzumab bests rituximab for pfs in follicular lymphoma
-
4:38
an in-depth look at treatment of follicular lymphoma
-
4:07
rituximab, obinutuzumab, and ofatumumab in cll
-
1:32
deciding on rituximab versus obinutuzumab in follicular lymphoma
-
4:10
obinutuzumab doubles remission duration in patients with relapsed, indolent non-hodgkin lymphoma
-
7:57
asco 2015: obinutuzumab doubles remission duration in relapsed, indolent non-hodgkin lymphoma
-
11:49
how do monoclonal antibodies work? rituximab, infliximab, adalimumab and others
-
2:02
the monoclonal antibodies rituximab, obinutuzumab, and ofatumumab all target cd20...
-
8:24
cd-20 antibodies in chronic lymphocytic leukemia